MARKET

ADTX

ADTX

ADiTx Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.840
+0.110
+4.03%
After Hours: 2.810 -0.03 -1.06% 17:50 05/07 EDT
OPEN
2.730
PREV CLOSE
2.730
HIGH
2.890
LOW
2.700
VOLUME
174.53K
TURNOVER
--
52 WEEK HIGH
9.58
52 WEEK LOW
1.620
MARKET CAP
14.99M
P/E (TTM)
-2.8233
1D
5D
1M
3M
1Y
5Y
Aditxt Signs Channel Partner Agreement with Meridian HSN to Make AditxtScore for COVID-19 Available to its Network of Healthcare Provider Partners
Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Meridian Health Services Network
Benzinga · 3d ago
BRIEF-Aditxt Signs Channel Partner Agreement With Meridian Hsn To Make Aditxtscore™ For Covid-19 Available To Its Network Of Healthcare Provider Partners
reuters.com · 3d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 5d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers  
Benzinga · 5d ago
Aditxt to Establish State-of-the-Art Immune Monitoring Center in Richmond, VA
Aditxt (Aditx Therapeutics, Inc.) (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced plans to build a high-capacity AditxtScore™ Center in Richmond, VA in the second half of 2021. Aditxt is ta...
PR Newswire · 5d ago
Aditx Therapeutics' Aditxt Outlines Plans To Build High-Capacity AditxtScore Center In Richmond, Virginia In H2'21
Aditxt (Aditx Therapeutics, Inc.) (NASDAQ:ADTX), a biotech innovation company focused on improving the health of the immune system, today announced plans to build a high-capacity AditxtScore™ Center in Richmond, VA
Benzinga · 5d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
There's a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and ADiTx Therapeutics (ADTX) with bullish sentiments.
SmarterAnalyst · 04/23 09:05
Aditxt Therapeutics names its first chief communications officer
Aditx Therapeutics (ADTX) announces that Sunny Uberoi has joined the organization as its Chief Communications Officer.He will be responsible for leading global corporate communications, investor relations, and government affairs. Most recently, he served a...
Seekingalpha · 04/13 12:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADTX. Analyze the recent business situations of ADiTx Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADTX stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 11
Institutional Holdings: 222.97K
% Owned: 4.22%
Shares Outstanding: 5.28M
TypeInstitutionsShares
Increased
1
35
New
5
205.66K
Decreased
1
14.24K
Sold Out
5
326.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/President/Chief Executive Officer/Director
Amro Albanna
Chief Financial Officer
Corinne Pankovcin
Chief Operating Officer
Rowena Albanna
Other/Director
Shahrokh Shabahang
Independent Director
Laura Anthony
Independent Director
Brian Brady
Independent Director
Namvar Kiaie
Independent Director
Jeffrey Runge
No Data
About ADTX
Aditx Therapeutics, Inc. is a pre-clinical stage, life sciences company. The Company is focused on developing technologies on improving the health of the immune system through immune reprogramming and monitoring. The Company’s immune reprogramming technology is at the pre-clinical stage and is designed to retrain the immune system to induce tolerance. The Company’s immune monitoring technology is designed to provide a personalized profile of the immune system. The Company is developing nucleic acid-based technology, Apoptotic DNA Immunotherapy (ADi) that mimics the way human body naturally induces tolerance to its tissues. The Company is developing Aditxt Immune Monitor (AiM), which provides a personalized comprehensive profile of the immune system.

Webull offers kinds of ADiTx Therapeutics Inc stock information, including NASDAQ:ADTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADTX stock methods without spending real money on the virtual paper trading platform.